

Akemi Kosaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9661005/publications.pdf>

Version: 2024-02-01

21
papers

804
citations

687363

13
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

1469
citing authors

#	ARTICLE	IF	CITATIONS
1	STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2014, 2, 1199-1208.	3.4	185
2	Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 705-716.	4.2	128
3	Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 877-890.	4.2	126
4	Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. , 2013, 1, 21.		85
5	Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1169356.	4.6	34
6	Effects of STING stimulation on macrophages: STING agonists polarize into "classically" or "alternatively" activated macrophages?. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 285-287.	3.3	29
7	CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	27
8	Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 549-554.	2.1	26
9	Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 408-414.	2.1	19
10	Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2022, 11, 2021619.	4.6	19
11	Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy. <i>Oncolmmunology</i> , 2015, 4, e999523.	4.6	16
12	Intratumoral injection of IFN- γ induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 521-527.	2.1	15
13	Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 989-999.	4.2	15
14	Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1466771.	4.6	14
15	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 207.	4.4	13
16	Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2021, 10, 1856545.	4.6	13
17	A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2301-2312.	4.2	11
18	Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3421-3434.	4.2	11

#	ARTICLE	IF	CITATIONS
19	IFN- γ - and IL-17-producing CD8 ⁺ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity. , 2021, 9, e002426.		8
20	A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy. Cancer Science, 2021, 112, 2705-2713.	3.9	6
21	A tumor metastasis-associated molecule <sc>TWIST1 </sc> is a favorable target for cancer immunotherapy due to its immunogenicity. Cancer Science, 2022, 113, 2526-2535.	3.9	4